Growth Metrics

Innoviva (INVA) Other Non-Current Assets (2010 - 2026)

Innoviva posted quarterly Other Non-Current Assets of $40.5 million for Q1 2026, down 1.8% year-on-year from $41.3 million in Q1 2025, and down 0.53% on a QoQ basis from $40.7 million in Q4 2025.

Innoviva (INVA) has 17 years of Other Non-Current Assets data on file, last reported at $40.5 million in Q1 2026.

  • For the quarter ending Q1 2026, Other Non-Current Assets fell 1.8% year-over-year to $40.5 million; the trailing twelve-month figure through Mar 2026 stood at $40.5 million (down 1.8% YoY), and the FY2025 full-year result was $40.7 million, down 1.77% from the prior year.
  • Other Non-Current Assets for Q1 2026 stood at $40.5 million, down from $40.7 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $41.5 million in Q4 2024 and bottomed at $313000.0 in Q1 2022.
  • The 5-year median for Other Non-Current Assets is $3.6 million (2023), against an average of $14.1 million.
  • The widest annual swing landed in 2022, when Other Non-Current Assets jumped 38981.82%; it then plunged 60.71% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $4.3 million in 2022, then decreased by 24.01% to $3.3 million in 2023, then soared by 1169.57% to $41.5 million in 2024, then dropped by 1.77% to $40.7 million in 2025, then declined by 0.53% to $40.5 million in 2026.
  • The last three Other Non-Current Assets figures came in at $40.5 million (Q1 2026), $40.7 million (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Other Non-Current Assets (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 12.40 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 60,000.00
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 1.26 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 2.13 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 63.55 Mn
10 Innoviva 1.60 Bn 992.84 Mn 75.83 Mn 40.53 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 40.53 Mn
Dec 31, 2025 40.74 Mn
Sep 30, 2025 1.10 Mn
Jun 30, 2025 41.18 Mn
Mar 31, 2025 41.27 Mn
Dec 31, 2024 41.48 Mn
Sep 30, 2024 2.80 Mn
Jun 30, 2024 2.98 Mn
Mar 31, 2024 3.11 Mn
Dec 31, 2023 3.27 Mn
Sep 30, 2023 3.44 Mn
Jun 30, 2023 3.56 Mn
Mar 31, 2023 3.89 Mn
Dec 31, 2022 4.30 Mn
Sep 30, 2022 4.62 Mn
Jun 30, 2022 1.16 Mn
Mar 31, 2022 313,000.00
Dec 31, 2021 11,000.00
Sep 30, 2021 136,000.00
Jun 30, 2021 162,000.00
Mar 31, 2021 188,000.00
Dec 31, 2020 214,000.00
Sep 30, 2020 239,000.00
Jun 30, 2020 264,000.00
Mar 31, 2020 288,000.00
Dec 31, 2019 312,000.00
Sep 30, 2019 48,000.00
Jun 30, 2019 37,000.00
Mar 31, 2019 37,000.00
Dec 31, 2018 37,000.00
Sep 30, 2018 37,000.00
Jun 30, 2018 37,000.00
Mar 31, 2018 37,000.00
Dec 31, 2017 37,000.00
Sep 30, 2017 37,000.00
Jun 30, 2017 37,000.00
Mar 31, 2017 37,000.00
Dec 31, 2016 37,000.00
Sep 30, 2016 40,000.00
Jun 30, 2016 58,000.00
Mar 31, 2016 18,000.00
Dec 31, 2015 18,000.00
Sep 30, 2015 15.81 Mn
Jun 30, 2015 16.57 Mn
Mar 31, 2015 17.34 Mn
Dec 31, 2014 18.10 Mn
Sep 30, 2014 19.95 Mn
Jun 30, 2014 22.39 Mn
Mar 31, 2014 833,000.00
Dec 31, 2013 833,000.00
Sep 30, 2013 833,000.00
Jun 30, 2013 833,000.00
Mar 31, 2013 833,000.00
Dec 31, 2012 833,000.00
Sep 30, 2012 833,000.00
Jun 30, 2012 2.10 Mn
Mar 31, 2012 2.31 Mn
Dec 31, 2011 2.51 Mn
Sep 30, 2011 893,000.00
Jun 30, 2011 893,000.00
Dec 31, 2010 3.34 Mn